John Marken Email & Phone Number

Seattle, Washington, United States

Seattle -South Lake Union

Cellular immunology, molecular biology, protein engineering, assay dev, technology development

Seattle

Genome editing tools, TALENS technology, neuron development control

Target discovery method developmentSuccessful antibody binding domain optimization against complex targetsphage displayMolecular cloning of antibody variable domains and functional characterizationAntibody based protein engineeringEvaluation of novel protein-target interactionsMammalian and bacterial protein expression

• Headed importation of Dyax phage display technology and first successful screening project. Performed on-cell screening.• Led importation of antibody affinity maturation technology• Developed method to enhance stable cell line production for secreted proteins from CHO pools by live flow cell sorting. Decreased time to obtain high producing clones by several months. Allowed production of soluble material from CHO pools without cloning.• Member of scientific research team communicating directly with outside partners such as Wyeth Pharmaceuticals. Platform research, assays, candidate validation.• Key contributor in the development of two drugs Tru015, Tru016 currently in clinical trials. Platform development, expression optimization, FACS, in vitro assays and early phase candidate cell line development. • Contributed to platform development of bi-specific molecules. Investigated properties of domain combinations, stability, function of resultant proteins.

• Cloning, validation of drug target candidates resulting from human genomics, cDNA library sequencing, and array studies. Studied B7H3a/b, siglec11,12, Rank, kinases, others. Utilized phage derived ScFvFc to study expression, function.• Successful proof of concept study for functional cloning using on-cell CAT phage display, Intrabody functional knock-out technology, Lentivirus transduction systems, MACS cell sorting, in vitro assays. • Molecular biology and in vivo work for RANK receptor knock out studies, supports current Amgen therapeutics.• Successful phage screen (CAT) for ULBP1 fusion protein.• Studies to support and improve high throughput sequencing using cDNA library subtraction. Genomic sequence data mining, cDNA array expression analysis.

see Amgen above: Immunex was acquired by Amgen.

Expression cloning of the "Tumor Associated Antigen L6” (TM4SF-1) an oncology target candidate. Molecular and expression studies to characterize TM4SF-1 and the L6 chimeric antibody including site specific mutagenesis, chimera synthesis. Expression cloning and study of other targets. Fusion protein construction, transfection, affinity purification of various fusion molecules. Mutagenesis studies on CD40/CD40L and antibody epitope mapping. Hybridoma screening for other targets. Synthesis of oligonucleotides for sub group. Expression cloning of various targets.

Glycobiology, molecular biology